In a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
Import tariff of 15%: significant implications for pharmaceutical firms
Latest NewsIn the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the imposition of the same rate on EU investments exceeding US$600m in the US, without formal resistance. Industry associations have reacted with strong criticism.
Bayer targets leading position in HER2-positive NSCLC
Latest NewsThe potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for the treatment of HER2-positive non-small cell lung cancer (NSCLC).
From Brisbane to London to Paris: Vicebio´s Sanofi deal
Latest NewsFrom Brisbane to London to Paris: Australian vaccine innovation sparks US$1.15 billion deal with french Sanofi with an additional US$450 million tied to clinical milestones and underscoring a major commitment to next-generation respiratory vaccines.
Abivax soars 500% on TOP-Line data
Latest NewsIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
Westwards: AstraZeneca Shifts Gears with $50 Billion US Investment
Latest NewsAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub.
Fine and speciality chemicals industry keeps its cool
BackgroundResilience and quality connections define Chemspec Europe 2025.
Eight healthy children born with DNA from three people
BackgroundA landmark study in the UK shows that mitochondrial replacement therapy can prevent babies from inheriting diseases caused by mutant mitochondria.
Carbios is back with a partnership in the automotive tyre industry
Latest NewsFrench CARBIOS SA signs strategic agreement with Indorama Ventures and Michelin amid broader company transition and sees itself back on track. Before opening of its production plant (delayed to later in 2026), the company has shown some success in concluding production agreements with several larger industry corporates.
One Bioscience raises €15m to leverage AI tumour profiling
Latest NewsParis-based One Biosciences, a pioneering “techbio” company at the intersection of artificial intelligence and oncology, has announced a €15 million Series A funding round to accelerate the clinical application of its flagship technology.
Bold UK-Strategy in Life Sciences
Latest NewsThe UK Government launched a ten-year Life Sciences Sector Plan to drive innovation and health reform within the NHS. This Life Sciences Sector Plan is part of its broader Industrial Strategy.